Logo image
Back
Association Between Blood Spot Transforming Growth Factor-beta and Patent Ductus Arteriosus in Extremely Low-Birth Weight Infants
Journal article   Open access   Peer reviewed

Association Between Blood Spot Transforming Growth Factor-beta and Patent Ductus Arteriosus in Extremely Low-Birth Weight Infants

Girija Natarajan, Seetha Shankaran, Scott A. McDonald, Abhik Das, Richard A. Ehrenkranz, Ronald N. Goldberg, Barbara J. Stoll, Jon E. Tyson, Rosemary D. Higgins, Diana Schendel, …
Pediatric cardiology, v 34(1)
01 Jan 2013
DOI: https://doi.org/10.1007/s00246-012-0404-7
PMID: 22684193
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://europepmc.org/articles/pmc3704212?pdf=renderView
Accepted (AM)Open Access (License Unspecified),  Open

Abstract

Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Life Sciences & Biomedicine Pediatrics Science & Technology
Permanent ductal closure involves anatomic remodeling, in which transforming growth factor (TGF)-beta appears to play a role. Our objective was to evaluate the relationship, if any, between blood spot TGF-beta on day 3 and day 7 of life and patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Prospective observational study involving ELBW infants (n = 968) in the National Institute of Child Health and Human Development Neonatal Research Network who had TGF-beta measured on filter paper spot blood samples using a Luminex assay. Infants with a PDA (n = 493) were significantly more immature, had lower birth weights, and had higher rates of respiratory distress syndrome than those without PDA (n = 475). TGF-beta on days 3 and 7 of life, respectively, were significantly lower among neonates with PDA (median 1,177 pg/ml [range 642-1,896]; median 1,386 pg/ml [range 868-1,913]) compared with others without PDA (median 1,334 pg/ml [range 760-2,064]; median 1,712 pg/ml [range 1,014-2,518 pg/ml]). The significant difference persisted when death or PDA was considered a composite outcome. TGF-beta levels were not significantly different among subgroups of infants with PDA who were not treated (n = 51) versus those who were treated medically (n = 283) or by surgical ligation (n = 159). TGF-beta was not a significant predictor of death or PDA (day 3 odds ratio [OR] 0.99, 95 % confidence interval [CI] 0.83-1.17; day 7 OR 0.88, 95 % CI 0.74-1.04) on adjusted analyses. Our results suggest that blood spot TGF-beta alone is unlikely to be a reliable biomarker of a clinically significant PDA or its responsiveness to treatment.

Metrics

6 Record Views
2 citations in Web of Science
2 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
International collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Pediatrics
Logo image